Stay updated on Alvocidib Biomarker AML Phase 2 Clinical Trial
Sign up to get notified when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.

Latest updates to the Alvocidib Biomarker AML Phase 2 Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows that the study is no longer looking for participants, signaling that enrollment has ceased. It also includes new help/navigation items and a formatting change to the Intervention/Treatment header as part of a UI/text refresh.SummaryDifference0.4%

- Check19 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4. This represents a version update with no changes to the study content.SummaryDifference0.0%

- Check41 days agoChange DetectedThe page now displays Revision: v3.5.4, updating the site revision from the previous v3.5.3. This indicates a software/version update rather than a change to the study data or layout.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision changed from v3.5.2 to v3.5.3 on the page, indicating a deployed update to the study entry. This version bump does not modify the study information presented to users.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. No visible changes to study data, eligibility criteria, or page navigation.SummaryDifference0.0%

- Check91 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Alvocidib Biomarker AML Phase 2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alvocidib Biomarker AML Phase 2 Clinical Trial page.